Clinical trials: Psoriasis Genital
Psoriasis, Psoriasis Genital
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis: A Prospective Randomized Controlled Study.
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat flexural and/or genital psoriasis in adult patients of both genders.
- Trial name
- NCT07892339
- Testing
- Crisaborole 2% topical ointment, tacrolimus ointment 0.1%
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Psoriasis Palmaris, Psoriasis Genital
Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population.Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar…
- Conditions
- Psoriasis Palmaris, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Plantaris
- Trial name
- ZODIPSO (NCT05938361)
- Testing
- Psoriasis clinical assessments, Quality of life evaluation, Satisfaction assessment
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Clin4all
Moderate to Severe Genital Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
- Trial name
- NCT06611163
- Testing
- Tildrakizumab 100 mg
- Where
- 56 sites in United States, Bulgaria and 3 more
- Volunteers
- 206 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Flexural Psoriasis (Also Known as Inverse or Intertriginous Psoriasis) and Genital Psoriasis
EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL.
Psoriasis affecting sensitive anatomical regions, such as the skin folds (flexural or inverse psoriasis) and genitalia, presents unique therapeutic challenges.
- Trial name
- NCT07543640
- Testing
- Methotrexate, Roflumilast 500 Mcg Oral Tablet
- Volunteers
- 56 people
- Sponsor
- Eman Raafat Said
Palmoplantar Psoriasis, Genital Psoriasis
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
- Trial name
- NCT06042920
- Testing
- Deucravacitinib
- Where
- 31 sites in United States, Argentina and 1 more
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb
Genital Psoriasis, Scalp Psoriasis
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- UnlIMMited (NCT05969223)
- Testing
- Risankizumab
- Where
- 38 sites in United States
- Volunteers
- 214 people
- Sponsor
- AbbVie
Psoriasis, Psoriasis Vulgaris
A Pilot Study to Explore the Role of Gut Flora in Psoriasis
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Psoriasis.
- Conditions
- Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face
- Trial name
- NCT04099979
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Genital Psoriasis
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to…
- Trial name
- NCT06029257
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 110 people
- Sponsor
- Almirall, S.A.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Genital Psoriasis, Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
- Trial name
- IXORA-Q (NCT02718898)
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company